HCW Biologics (HCWB) shares were sharply higher in Monday's premarket session after it said it received US Food and Drug Administration clearance to launch a phase 1 trial to evaluate HCW9302 for the treatment of moderate-to-severe alopecia areata.
The company said the goal of the trial is to determine a safe dose of HCW9302 that effectively increases regulatory T cell activity in patients.
"Once we achieve this objective, we will rapidly expand clinical development of HCW9302 in phase 2 studies in patients with other autoimmune diseases and inflammatory conditions," Chief Executive Hing Wong said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。